SAB Biotherapeutics (SABS) Equity Ratio (2020 - 2026)

SAB Biotherapeutics has reported Equity Ratio for 7 years, with the latest figure at 0.91 in Q1 2026.

• For the quarter ending Q1 2026, Equity Ratio rose 62.86% year-over-year to 0.91; the trailing twelve-month figure through Mar 2026 stood at 0.91 (up 62.86% YoY), and the FY2025 full-year result was 0.88, up 49.19% from the prior year.
• Equity Ratio for Q1 2026 stood at 0.91, up from 0.88 in the prior quarter.
• The five-year high for Equity Ratio was 0.91 in Q1 2026, with the low at 0.4 in Q2 2025.
• Historically, Equity Ratio has averaged 0.66 across 5 years, with a median of 0.61 in 2022.
• Annual changes were most pronounced in 2022 — Equity Ratio jumped 94.41% — and 2025, when it tumbled 46.48%.
• SAB Biotherapeutics' Equity Ratio stood at 0.61 in 2022, then grew by 11.88% to 0.68 in 2023, then retreated by 13.92% to 0.59 in 2024, then jumped by 49.19% to 0.88 in 2025, then advanced by 4.33% to 0.91 in 2026.
• The last three Equity Ratio figures came in at 0.91 (Q1 2026), 0.88 (Q4 2025), and 0.9 (Q3 2025), per Business Quant data.